The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
대표청구항▼
1. An isolated nucleic acid encoding the amino acid sequence of an antibody or antigen binding fragment capable of binding to Chemokine (C-X-C motif) receptor 3 (CXCR3), said antibody or antigen binding fragment comprising six complementarity determining regions (CDRs): heavy chain variable domain (
1. An isolated nucleic acid encoding the amino acid sequence of an antibody or antigen binding fragment capable of binding to Chemokine (C-X-C motif) receptor 3 (CXCR3), said antibody or antigen binding fragment comprising six complementarity determining regions (CDRs): heavy chain variable domain (VH) CDR1, VH CDR2, VH CDR3, light chain variable domain (VL) CDR1, VL CDR2, and VL CDR3, wherein:a) VH CDR1 is selected from the group consisting of: SEQ ID NO: 116, SEQ ID NO: 228, SEQ ID NO: 368, and SEQ ID NO: 543;b) VH CDR2 is selected from the group consisting of: SEQ ID NO: 118, SEQ ID NO: 174, SEQ ID NO: 230, SEQ ID NO: 370, and SEQ ID NO: 545;c) VH CDR3 is selected from the group consisting of: SEQ ID NO: 120, SEQ ID NO: 176, SEQ ID NO: 232, SEQ ID NO: 372, and SEQ ID NO: 547;d) VL CDR1 is selected from the group consisting of: SEQ ID NO: 123, SEQ ID NO: 179, SEQ ID NO: 235, SEQ ID NO: 375, and SEQ ID NO: 550;e) VL CDR2 is selected from the group consisting of: SEQ ID NO: 125, SEQ ID NO: 181, SEQ ID NO: 237, SEQ ID NO: 377, and SEQ ID NO: 552; andf) VL CDR3 is selected from the group consisting of: SEQ ID NO: 127, SEQ ID NO:239, SEQ ID NO: 379, and SEQ ID NO: 554. 2. The isolated nucleic acid of claim 1, wherein the antibody or fragment is chimeric, CDR grafted, mutated, mutated to remove one or more deamidation site, human, humanized, humanized and back-mutated, synthetic, or recombinant. 3. The isolated nucleic acid of claim 1, wherein the antibody or fragment is capable of binding to a polypeptide comprising a peptide selected from the group consisting of: a) a peptide comprising the amino acid sequence SEQ ID NO:71;b) a peptide comprising the amino acid sequence SEQ ID NO:72;c) a peptide comprising the amino acid sequence SEQ ID NO:73;d) a peptide comprising the amino acid sequence SEQ ID NO:74;e) a peptide comprising the amino acid sequence SEQ ID NO:75;f) a peptide comprising the amino acid sequence SEQ ID NO:76;g) a peptide comprising the amino acid sequence SEQ ID NO:77;h) a peptide comprising the amino acid sequence SEQ ID NO:78;i) a peptide comprising the amino acid sequence SEQ ID NO:79;j) a peptide comprising the amino acid sequence SEQ ID NO:80;k) a peptide comprising residues 1-58 of SEQ ID NO:1;l) a peptide comprising residues 1-16 of SEQ ID NO:1; andm) a peptide comprising residues 1-37 of SEQ ID NO:1,wherein X indicates any amino acid. 4. The isolated nucleic acid of claim 1, wherein the antibody or fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26-33, 38, 40, 42, 44, 46-48, 55, 57, 59, 61 and 63-66; andwherein the light chain variable region comprises a sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 34-37, 39, 41, 43, 45, 49-54, 56, 58, 60, 61 and 67-70. 5. The isolated nucleic acid of claim 4, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26-33, 38, 40, 42, 44, 46-48, 55, 57, 59, 61 and 63-66; andwherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 34-37, 39, 41, 43, 45, 49-54, 56, 58, 60, 61 and 67-70. 6. The isolated nucleic acid of claim 1, wherein said antibody or fragment comprises 3 CDRs selected from the group of variable domain CDR sets consisting of: Clone 12 VH CDR set: SEQ ID NO: 116, SEQ ID NO: 118, and SEQ ID NO: 120;Clone 12VL CDR set: SEQ ID NO: 123, SEQ ID NO: 125, and SEQ ID NO: 127;Clone 135 VH CDR set: SEQ ID NO: 368, SEQ ID NO: 174, and SEQ ID NO: 176;Clone 135 VL CDR set: SEQ ID NO: 179, SEQ ID NO: 181, and SEQ ID NO: 379;Clone 4 VH CDR set: SEQ ID NO: 228, SEQ ID NO: 230, and SEQ ID NO: 232;Clone 4 VL CDR set: SEQ ID NO: 235, SEQ ID NO: 237, and SEQ ID NO: 239;Clone 53 VH CDR set: SEQ ID NO: 368, SEQ ID NO: 370, and SEQ ID NO: 372;Clone 53 VL CDR set: SEQ ID NO: 375, SEQ ID NO: 377, and SEQ ID NO: 379;Clone 82 VH CDR set: SEQ ID NO: 543, SEQ ID NO: 545, and SEQ ID NO: 547;andClone 82 VL CDR set: SEQ ID NO: 550, SEQ ID NO: 552, and SEQ ID NO: 554. 7. The isolated nucleic acid of claim 1, wherein said antibody or fragment comprises two variable domain CDR sets selected from a group consisting of: Clone 12 VH CDR set and Clone 12 VL CDR set;Clone 135 VH CDR set and Clone 135 VL CDR set;Clone 4 VH CDR set and Clone 4 VL CDR set;Clone 53 VH CDR set and Clone 53 VL CDR set;andClone 82 VH CDR set and Clone 82 VL CDR set. 8. The isolated nucleic acid of claim 1, wherein the antibody or fragment comprises a combination of heavy chain and light chain variable regions selected from the group consisting of: SEQ ID NOs: 18 and 19; SEQ ID NOs: 20 and 21; SEQ ID NOs: 22 and 23;SEQ ID NOs: 24 and 25; SEQ ID NOs: 22 and 25; SEQ ID NOs: 24 and 23;SEQ ID NOs: 26 and 34; SEQ ID NOs: 26 and 37; SEQ ID NOs: 27 and 35;SEQ ID NOs: 27 and 36; SEQ ID NOs: 28 and 34; SEQ ID NOs: 22 and 21;SEQ ID NOs: 20 and 23; SEQ ID NOs: 24 and 21; SEQ ID NOs: 20 and 25;SEQ ID NOs: 29 and 23; SEQ ID NOs: 30 and 23; SEQ ID NOs: 31 and 23;SEQ ID NOs: 32 and 23; SEQ ID NOs: 33 and 23; SEQ ID NOs: 2 and 3;SEQ ID NOs: 4 and 5; SEQ ID NOs: 6 and 7; SEQ ID NOs: 8 and 9;SEQ ID NOs: 55 and 56; SEQ ID NOs: 57 and 58; SEQ ID NOs: 59 and 60;SEQ ID NOs: 61 and 62; SEQ ID NOs: 10 and 11; SEQ ID NOs: 12 and 13;SEQ ID NOs: 14 and 15; SEQ ID NOs: 16 and 17; SEQ ID NOs: 38 and 39;SEQ ID NOs: 40 and 41; SEQ ID NOs: 42 and 43 SEQ ID NOs: 44 and -45;SEQ ID NOs: 40 and 43; SEQ ID NOs: 42 and 41; SEQ ID NOs: 42 and 49;SEQ ID NOs: 42 and 50; SEQ ID NOs: 42 and 51; SEQ ID NOs: 42 and 52;SEQ ID NOs: 42 and 53; SEQ ID NOs: 42 and 54; SEQ ID NOs: 46 and 43;SEQ ID NOs: 47 and 43; SEQ ID NOs: 48 and 43; SEQ ID NOs: 40 and 49;SEQ ID NOs: 40 and 51; SEQ ID NOs: 48 and 49; SEQ ID NOs: 48 and 51;SEQ ID NOs: 63 and 67; and SEQ ID NOs: 63 and 68. 9. The isolated nucleic acid of claim 1, wherein the antibody or fragment is capable of preferentially binding to A-isoform of CXCR3. 10. A vector comprising the isolated nucleic acid of claim 1. 11. A vector comprising the isolated nucleic acid of claim 7. 12. A vector comprising the isolated nucleic acid of claim 8. 13. An isolated host cell comprising the vector of claim 10. 14. An isolated host cell comprising the vector of claim 11. 15. The host cell according to claim 13, wherein said host cell is a cell selected from the group consisting of an E. coli cell, a COS cell, and a Chinese hamster ovary (CHO) cell. 16. The host cell according to claim 14, wherein said host cell is a cell selected from the group consisting of an E. coli cell, a COS cell, and a Chinese hamster ovary (CHO) cell. 17. A method of producing the antibody or fragment encoded by the isolated nucleic acid of claim 1, comprising culturing a host cell comprising a vector comprising the isolated nucleic acid of claim 1 in a culture medium under conditions suitable to produce said antibody or fragment. 18. A method of producing the antibody or fragment encoded by the isolated nucleic acid of claim 7, comprising culturing a host cell comprising a vector comprising the isolated nucleic acid of claim 7 in a culture medium under conditions suitable to produce said antibody or fragment. 19. The method of claim 17, wherein said antibody or fragment is capable of preferentially binding to A-isoform of CXCR3. 20. An isolated nucleic acid encoding the heavy chain variable region of an antibody or antigen binding fragment capable of binding to Chemokine (C-X-C motif) receptor 3 (CXCR3), said antibody or antigen binding fragment comprising six complementarity determining regions (CDRs): heavy chain variable domain (VH) CDR1, VH CDR2, VH CDR3, light chain variable domain (VL) CDR1, VL CDR2, and VL CDR3, wherein: a) VH CDR1 is selected from the group consisting of: SEQ ID NO: 116, SEQ ID NO: 228, SEQ ID NO: 368, and SEQ ID NO: 543;b) VH CDR2 is selected from the group consisting of: SEQ ID NO: 118, SEQ ID NO: 174, SEQ ID NO: 230, SEQ ID NO: 370, and SEQ ID NO: 545;c) VH CDR3 is selected from the group consisting of: SEQ ID NO: 120, SEQ ID NO: 176, SEQ ID NO: 232, SEQ ID NO: 372, and SEQ ID NO: 547;d) VL CDR1 is selected from the group consisting of: SEQ ID NO: 123, SEQ ID NO: 179, SEQ ID NO: 235, SEQ ID NO: 375, and SEQ ID NO: 550;e) VL CDR2 is selected from the group consisting of: SEQ ID NO: 125, SEQ ID NO: 181, SEQ ID NO: 237, SEQ ID NO: 377, and SEQ ID NO: 552; andg) VL CDR3 is selected from the group consisting of: SEQ ID NO: 127, SEQ ID NO: 239, SEQ ID NO: 379, and SEQ ID NO: 554, andwherein said heavy chain variable region comprises an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26-33, 38, 40, 42, 44, 46-48, 55, 57, 59, 61 and 63-66. 21. The isolated nucleic acid of claim 20, wherein the heavy chain variable region comprises a sequence at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26-33, 38, 40, 42, 44, 46-48, 55, 57, 59, 61 and 63-66. 22. The isolated nucleic acid of claim 20, wherein the heavy chain variable region comprises a sequence at least 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26-33, 38, 40, 42, 44, 46-48, 55, 57, 59, 61 and 63-66. 23. The isolated nucleic acid of claim 20, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26-33, 38, 40, 42, 44, 46-48, 55, 57, 59, 61 and 63-66. 24. A vector comprising the isolated nucleic acid of claim 20. 25. An isolated host cell comprising the vector of claim 24. 26. The host cell according to claim 25, wherein said host cell is a cell selected from the group consisting of an E. coli cell, a COS cell, and a Chinese hamster ovary (CHO) cell. 27. A method of producing the antibody or fragment encoded by the isolated nucleic acid of claim 20, comprising culturing a host cell comprising a vector comprising the isolated nucleic acid of claim 20 in a culture medium under conditions suitable to produce said antibody or fragment. 28. An isolated nucleic acid encoding the light chain variable region of an antibody or antigen binding fragment capable of binding to Chemokine (C-X-C motif) receptor 3 (CXCR3), said antibody or antigen binding fragment comprising six complementarity determining regions (CDRs): heavy chain variable domain (VH) CDR1, VH CDR2, VH CDR3, light chain variable domain (VL) CDR1, VL CDR2, and VL CDR3, wherein:a) VH CDR1 is selected from the group consisting of: SEQ ID NO: 116, SEQ ID NO: 228, SEQ ID NO: 368, and SEQ ID NO: 543;b) VH CDR2 is selected from the group consisting of: SEQ ID NO: 118, SEQ ID NO: 174, SEQ ID NO: 230, SEQ ID NO: 370, and SEQ ID NO: 545;c) VH CDR3 is selected from the group consisting of: SEQ ID NO: 120, SEQ ID NO: 176, SEQ ID NO: 232, SEQ ID NO: 372, and SEQ ID NO: 547;d) VL CDR1 is selected from the group consisting of: SEQ ID NO: 123, SEQ ID NO: 179, SEQ ID NO: 235, SEQ ID NO: 375, and SEQ ID NO: 550;e) VL CDR2 is selected from the group consisting of: SEQ ID NO: 125, SEQ ID NO: 181, SEQ ID NO: 237, SEQ ID NO: 377, and SEQ ID NO: 552; and f) VL CDR3 is selected from the group consisting of: SEQ ID NO: 127, SEQ ID NO: 239, SEQ ID NO: 379, and SEQ ID NO: 554, andwherein said light chain variable region comprises an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 34-37, 39, 41, 43, 45, 49-54, 56, 58, 60, 62 and 67-70. 29. The isolated nucleic acid of claim 28, wherein said light chain variable region comprises an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 34-37, 39, 41, 43, 45, 49-54, 56, 58, 60, 62 and 67-70. 30. The isolated nucleic acid of claim 28, wherein said light chain variable region comprises an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 41, 43, 45, and 49-54. 31. The isolated nucleic acid of claim 28, wherein said light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 41, 43, 45, and 49-54. 32. The isolated nucleic acid of claim 20, wherein said heavy chain variable region comprises 3 CDRs selected from the group of variable domain CDR sets consisting of: Clone 12 VH CDR set: SEQ ID NO: 116, SEQ ID NO: 118, and SEQ ID NO: 120;Clone 135 VH CDR set: SEQ ID NO: 368, SEQ ID NO: 174, and SEQ ID NO: 176;Clone 4 VH CDR set: SEQ ID NO: 228, SEQ ID NO: 230, and SEQ ID NO: 232;Clone 53 VH CDR set: SEQ ID NO: 368, SEQ ID NO: 370, and SEQ ID NO: 372; andClone 82 VH CDR set: SEQ ID NO: 543, SEQ ID NO: 545, and SEQ ID NO: 547. 33. The isolated nucleic acid of claim 28, wherein said light chain variable region comprises 3 CDRs selected from the group of variable domain CDR sets consisting of: Clone 12 VL CDR set: SEQ ID NO: 123, SEQ ID NO: 125, and SEQ ID NO: 127;Clone 135 VL CDR set: SEQ ID NO: 179, SEQ ID NO: 181, and SEQ ID NO: 379;Clone 4 VL CDR set: SEQ ID NO: 235, SEQ ID NO: 237, and SEQ ID NO: 239;Clone 53 VL CDR set: SEQ ID NO: 375, SEQ ID NO: 377, and SEQ ID NO: 379;andClone 82 VL CDR set: SEQ ID NO:550, SEQ ID NO: 552, and SEQ ID NO: 554. 34. A vector comprising the isolated nucleic acid of claim 28. 35. An isolated host cell comprising the vector of claim 34. 36. The host cell according to claim 35, wherein said host cell is a cell selected from the group consisting of an E. coli cell, a COS cell, and a Chinese hamster ovary (CHO) cell. 37. A method of producing the antibody or fragment encoded by the isolated nucleic acid of claim 28, comprising culturing a host cell comprising a vector comprising the isolated nucleic acid of claim 28 in a culture medium under conditions suitable to produce said antibody or fragment.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (29)
Qin,Shixin; Kassam,Nasim; Newman,Walter, Antibodies which bind human CXCR3.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Loetscher Marcel,CHX ; Moser Bernhard,CHX ; Qin Shixin ; Mackay Charles R., IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor.
Kauffman Stuart Alan ; Ballivet Marc,CHX, Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and co.
Robinson Randy R. ; Liu Alvin Y. ; Horwitz Arnold H. ; Better Marc ; Wall Randolph ; Lei Shau-Ping ; Wilcox Gary L., Modular assembly of antibody genes, antibodies prepared thereby and use.
Kauffman Stuart Alan ; Ballivet Marc,CHX, Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides.
Kauffman Stuart Alan ; Ballivet Marc,CHX, Process for the production of stochastically-generated peptides,polypeptides or proteins having a predetermined propert.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.